Kura Oncology, Inc. Stock News
$10.46
0.57%
Nasdaq, Oct 09, 11:02 am EDT.
Market open.
Kura Oncology, Inc. Stock News
SAN DIEGO, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced that on October 1, 2026, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchas...
– KO-7246 regenerated functional β - cell mass and produced durable glycemic control in Type 1 and Type 2 diabetes models –
– $50 million financing led by BVF Partners with participation from the T1D Fund, Invus, Montanova, Eli Lilly and Company, Kura Oncology, members of the Kura leadership team, and multiple, successful biotech entrepreneurs – – Preclinical studies with KO-7246 demonstrate selective expansion of pancreatic β cells, increased endogenous insulin production, and improved glycemic control across multi...
– Seasoned public company CFO with deep biopharmaceutical finance experience across commercial operations, R&D portfolio management, investor relations, and capital allocation – SAN DIEGO, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA, “Kura”), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced the appointment of Jenni...
SAN DIEGO, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced that on September 1, 2026, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purc...
– KOMZIFTI ® (ziftomenib) generated $9.1 million in net product revenue, up 57% over 1Q, and approximately 115 new patient starts, up 35% over 1Q –
– Publication details the discovery and preclinical characterization of ziftomenib, including its potency, selectivity, and mechanism of action –
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
